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Liver cirrhosis mortality number has increased over the last decades. We aimed to estimate
the liver cirrhosis mortality rate and its trends for the first time by sex, age, geographical dis-
tribution, and cause in Iran.
Method
Iranian Death Registration System, along with demographic (Complete and Summary Birth
History, Maternal Age Cohort and Period methods) and statistical methods (Spatio-temporal
and Gaussian process regression models) were used to address the incompleteness and
misclassification and uncertainty of death registration system to estimate annual cirrhosis
mortality rate. Percentages of deaths were proportionally redistributed into cirrhosis due to
hepatitis B, C and alcohol use based on the data from the Global Burden of Disease (GBD)
2010 study.
Results
Liver cirrhosis mortality in elder patients was 12 times higher than that in younger patients at
national level in 2015. Over the 26 years, liver cirrhosis mortality in males has increased
more than that in females. Plus, the percentage of change in age adjusted mortality rate at
provincial levels varied between decreases of 64.53% to nearly 17% increase. Mortality rate
has increased until 2002 and then decreased until 2015.The province with highest mortality
rate in 2015 has nearly two times greater rate compare to the lowest. More than 60% of liver
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cirrhosis mortality cases at national level are caused by hepatitis B and C infection. The rate
of hepatitis B mortality is four times more than that from hepatitis C.
Conclusion
This study demonstrated an increasing and then decreasing pattern in cirrhosis mortality
that could be due to national vaccination of hepatitis B program. However monitoring, early
detection and treatment of risk factors of cirrhosis, mainly in high risk age groups and
regions are essential. Cirrhosis mortality could be diminished by using new non-invasive
methods of cirrhosis screening, hepatitis B vaccination, definite treatment of hepatitis C.
Introduction
Liver cirrhosis is the pathologic term used for end stage liver disease, which is characterized
with fibrosis of nodules [1]. It is reported as the 11th leading cause of death globally and also is
listed as one of the top ten causes of mortality in the USA [2, 3]. In Europe, 170000 deaths each
year are attributed to liver cirrhosis [4]. According to the reports by Global Burden of Disease
(GBD), the global cirrhosis mortality number almost doubled from 1990 to 2015. The same
pattern is observed in populations with high, middle, and low socioeconomic status and in
Eastern Mediterranean region countries. The mortality trend slightly increased in the men-
tioned countries over a period of 25 years.[3]. The mortality number reported in Afghanistan
had almost tripled from 1990 till 2015. This number had approximately doubled in Turkmeni-
stan, Armenia, Pakistan, and Iraq. On the contrary, mortality number in Turkey had decreased
[3]. The main risk factors for cirrhosis are hepatitis B, hepatitis C, alcohol consumption, and
nonalcoholic fatty liver disease [5, 6].
The epidemiology of liver cirrhosis mortality is reported in developed countries [7]. Unfor-
tunately, because of the poor quality of data, this issue has not been much studied in develop-
ing countries [6]. Quantifying the problem by using statistical models helps us to develop
preventive policies for managing liver cirrhosis. In addition, to the best of our knowledge there
is not a comprehensive assessment of cirrhosis mortality in Iran.
To obtain an estimation of this issue for the first time, we aimed to carry out an overview of
cirrhosis mortality rates from 1990 to 2015. It was also aimed to collect detailed information




In order to calculate mortality rate, we used Iranian Death registration system (DRS) and the
data obtained from the National and Sub national Burden of Diseases (NASBOD) project [8].
We addressed DRS incompleteness and misclassification by using demographic and statistical
methods. In addition, age and sex and urbanization distribution of Iranian population were
extracted from Iran national censuses[9]. Years of schooling (YOS) and wealth index (WI)
were calculated based on the results of Iran household expenditure survey[10]. We aimed to
estimate annual liver cirrhosis mortality rates, patterns, and temporal trends between 1990 and
2015 at national level and in 30 provinces in Iran.
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Definition
The International Classification of Diseases (ICD) code for underlying cause of death was used
as noted in death certificate[11]. There was no criteria to evaluate the ability of physicians who
filled the certificate of death. Data from ICD 10 was transformed to GBD by a physician and
verified by senior physician. In this study, a percentage of deaths in subgroup B18-B18.9,
I85-I85.9, K70-K70.9, K71.3-K71.51, K71.7, K72.1-K74.69, K74.9, K75.8-K76.0, K76.6, K76.7,
K76.9, Z52.6, and Z94.4 were proportionally redistributed into cirrhosis due to hepatitis B, C,
alcohol use, and other causes[12]. The proportions were calculated based on the data obtained
from the GBD 2010 study [12, 13]. Iran national population 2015 was considered as the stan-
dard population in this process to compare Iran subnational regions with each other.
Demographic modeling
To address incompleteness of Iranian Death Registration System in terms of child mortality,
we used Complete Birth History (CBH), and Summary of Birth History (SBH). To analyze
SBH, Maternal Age Cohort (MAC) and Maternal Age Period (MAP) methods were applied.
Generalized Growth Balance (GGB), Synthetic Extinct Generation (SEG) and a mixture of two
methods (GGB-SEG) were used for adult’s mortality incompleteness. More detailed informa-
tion is presented elsewhere [14, 15].
Statistical modeling
Briefly, spatio-temporal model was used to address misalignment in age, space and time of
data. Gaussian process regression (GPR) is used to extrapolate all-cause (age and sex specific)
mortality rates with a more consistent uncertainty [16–18]. The fraction of each causes of
death was exerted in all-cause mortality and was extrapolated using spatio-temporal model. A
simulation approach was used to estimate the uncertainty of predicted values. This mutual
process is a valid statistical method that is defined elsewhere [19, 20].
Misclassification correction
After addressing all-cause mortality rates, cause-specific rates were divided based on cause
fractions extracted from the original data. More detailed information is presented elsewhere
[19, 20]. For calculating the cause specific liver cirrhosis mortality, we divided the number of
deaths for each cause of cirrhosis into all the same year’s cirrhosis deaths in the same provinces
and also in national level, and then we calculate the proportion of each of the causes to the
total cirrhosis deaths. All graphs and maps were prepared using R statistical software version
3.1.2 [21]. In addition, to apply direct age standardized approach, we used “Epitools” package
in R software [22].The more detail on the above mentioned method is available on S1 File.
Results
Between 1990 and 2015, the absolute number of cirrhosis deaths was initially increased until
2002, and then it decreased in 2015 (Fig 1 and S1 Table).
Vaccination of hepatitis B was initiated in 1993 and reached the maximum level of percent-
age of coverage in 2000 at national level. Absolute number of cirrhosis mortality was increas-
ing till 2002 and then decreasing at national level. (Fig 2)
There was a 39% reduction in age-standardized cirrhosis mortality rate from 0.99 (95% CI:
0.77–1.27) per 100000 in 1990 to 0.60 (95% CI: 0.48–0.75) per 100000 in 2015 at national level.
(Table 1).
Liver cirrhosis mortality
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It seems that death from liver cirrhosis in male has increased faster than that in females
over the 26 years. In 1990 male to female age adjusted mortality ratio was approximately 0.88
and in 2015 it increased to approximately 0.99 (Fig 3).
At national level, the rate of cirrhosis mortality in the age group 80 to 85 years was approxi-
mately 12 times more than that in the age group 30 to 35 in 2015. This increase was even
higher in the age group 85 years and older by nearly 36 times. The pattern of increasing
Fig 1. Liver cirrhosis absolute number of deaths from 1990 to 2015 by province in Iran.
https://doi.org/10.1371/journal.pone.0198449.g001
Fig 2. Percentage of hepatitis B vaccination coverage in Iran from 1993 to 2015 and absolute number of deaths due to cirrhosis in Iran.
https://doi.org/10.1371/journal.pone.0198449.g002
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mortality is similar across all age groups in 1990. (Fig 4). The percent change of mortality
increased by 54% in the age group under 20 years while it decreased by 46% in the age group
over 20 years.
The percentage of change in age adjusted mortality rate at provincial levels varied between
a decreases of 64.53% to nearly 17% increase, over the 26 years. Although most of provinces
had decreeing rate during 26 years, two provinces showed an increasing pattern in mortality
rate. (Table 1). The lowest age-standardized liver cirrhosis mortality rate in 1990 was observed
in southwest of Iran with 0.53(95% CI: 0.42–0.67) per 100000. Age-standardized liver cirrhosis
mortality rate increased to its highest level in the mid-2000s. The north east part of Iran had
the highest age-standardized liver cirrhosis mortality rate in 2000 with 1.90(95% CI: 1.55–
2.33) per 100000. Finally in 2015, all rates decreased to the least at the provincial level with 0.47
(95% CI: 0.36–0.61) per 100000 (Table 1 and Fig 5).
The age adjusted cirrhosis mortality rate at provincial level was higher in females than in
males in 1990 but it was closely similar in both sexes in 2015 (Fig 3).
Table 1. National and provincial age standardized mortality rate in Iran (per 100,000) for both sexes and the percentage of change (Δ).
National/p provincial 1990(95% CI) 2000(95% CI) 2015(95% CI) % Δ 1990 to 2015 ANNUALLY PERCENT CHANGE
National 0.99(0.77–1.27) 1.50(1.21–1.87) 0.60(0.48–0.75) -39.39 -1.52
Markazi 0.90(0.73–1.11) 1.65(1.38–1.97) 0.77(0.63–0.93) -14.44 -0.56
Gilan 0.82(0.66–1.02) 1.17(0.97–1.42) 0.5(0.41–0.62) -39.02 -1.50
Mazandaran 0.87(0.7–1.09) 1.20(0.98–1.48) 0.59(0.47–0.75) -32.18 -1.24
Azarbaijan East 0.90(0.73–1.11) 1.47(1.22–1.78) 0.63(0.52–0.77) -30.00 -1.15
Azarbaijan West 0.79(0.64–0.98) 1.18(0.98–1.41) 0.5(0.42–0.61) -36.71 -1.41
Kermanshah 0.96(0.79–1.16) 1.69(1.42–2.01) 0.7(0.58–0.84) -27.08 -1.04
Khuzestan 0.57(0.46–0.7) 1.10(0.91–1.34) 0.5(0.41–0.61) -12.28 -0.47
Fars 0.73(0.59–0.9) 1.32(1.09–1.59) 0.67(0.55–0.83) -8.22 -0.32
Kerman 0.82(0.68–1) 1.22(1.03–1.45) 0.56(0.46–0.68) -31.71 -1.22
Khorasan, Razavi 1.10(0.88–1.37) 1.83(1.50–2.24) 0.58(0.47–0.72) -47.27 -1.82
Isfahan 0.79(0.62–1.01) 1.17(0.93–1.45) 0.51(0.4–0.64) -35.44 -1.36
Sistan and Baluchestan 0.96(0.73–1.25) 1.20(0.94–1.53) 0.63(0.5–0.79) -34.38 -1.32
Kordestan 0.95(0.75–1.19) 1.52(1.26–1.83) 0.55(0.46–0.66) -42.11 -1.62
Hamedan 0.98(0.81–1.18) 1.63(1.38–1.92) 0.82(0.68–0.98) -16.33 -0.63
Chahar Mahal and Bakhtiari 0.99(0.81–1.22) 1.24(1.03–1.49) 0.52(0.43–0.64) -47.47 -1.83
Lorestan 1.22(0.99–1.52) 1.66(1.39–1.99) 0.55(0.45–0.66) -54.92 -2.11
Ilam 1.01(0.82–1.26) 1.77(1.44–2.16) 0.66(0.53–0.82) -34.65 -1.33
Kohgiluyeh and Boyer-Ahmad 0.91(0.71–1.17) 1.29(1.03–1.62) 0.5(0.4–0.63) -45.05 -1.73
Bushehr 0.70(0.56–0.87) 1.32(1.09–1.59) 0.52(0.42–0.64) -25.71 -0.99
Zanjan 1.30(1.03–1.66) 1.57(1.31–1.87) 0.47(0.36–0.61) -63.85 -2.46
Semnan 1.00(0.78–1.28) 1.59(1.28–1.98) 0.87(0.69–1.1) -13.00 -0.50
Yazd 0.93(0.75–1.15) 1.41(1.15–1.72) 0.65(0.53–0.81) -30.11 -1.16
Hormozgan 0.53(0.42–0.67) 1.07(0.88–1.31) 0.62(0.49–0.78) 16.98 0.65
Tehran 1.72(1.23–2.39) 2.12(1.57–2.88) 0.61(0.45–0.83) -64.53 -2.48
Ardebil 0.92(0.75–1.13) 1.25(1.05–1.50) 0.58(0.48–0.7) -36.96 -1.42
Qom 1.02(0.77–1.34) 1.43(1.10–1.84) 0.54(0.42–0.69) -47.06 -1.81
Qazvin 1.23(1.00–1.50) 1.74(1.46–2.08) 0.68(0.57–0.83) -44.72 -1.72
Golestan 0.87(0.70–1.07) 1.54(1.29–1.84) 0.73(0.6–0.89) -16.09 -0.62
Khorasan, North 1.22(0.97–1.53) 1.90(1.55–2.33) 0.77(0.62–0.95) -36.89 -1.42
Khorasan, South 0.94(0.74–1.19) 1.60(1.29–1.98) 0.8(0.64–1) -14.89 -0.57
Alborz 0.59(0.46–0.77) 1.11(0.88–1.40) 0.64(0.51–0.81) 8.47 0.33
https://doi.org/10.1371/journal.pone.0198449.t001
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Generally, more than 60% of liver cirrhosis mortality at national level is due to hepatitis B
and C infections in 2015. However, hepatitis B and C in 1990 were responsible for approxi-
mately 70% of deaths. On the average, liver cirrhosis mortality rate due to hepatitis B was four
times more than that of hepatitis C. At provincial levels, the distribution of mortality causes
varied. In 2015, hepatitis B accounted for a range of 3% to 75% of liver cirrhosis mortality in
different provinces (Fig 6).
Liver cirrhosis mortality attributed to alcohol consumption was much more common in
males. In 1990, the ratio of male to female age adjusted mortality attributed to alcohol con-
sumption was 2.20; in some provinces, it even reached three. In 2015, male to female age
adjusted mortality ratio decreased to less than two. Liver cirrhosis mortality due to hepatitis C
was more common in females. Male to female age adjusted mortality ratio due to hepatitis C
was 0.64 in 1990 which increased to 0.74 in 2015. (Fig 7)
Discussion
This study showed that, based on Iranian data, liver cirrhosis mortality at national level
increased by 12 times in older age group (80 to 85) in 2015; as compared with the younger age
group (30 to 35). More than 60% of liver cirrhosis mortality at national level was due to hepati-
tis B and C infection. However, the distribution at subnational level varied consistent with the
Fig 3. Age adjusted mortality rate in females and males by province in Iran between 1990 and 2015.
https://doi.org/10.1371/journal.pone.0198449.g003
Liver cirrhosis mortality
PLOS ONE | https://doi.org/10.1371/journal.pone.0198449 January 15, 2019 6 / 13
prevalence of risk factors. On the average, the rate of liver cirrhosis mortality due to hepatitis B
was four times more than that of hepatitis C. To validate this study results, we have used the
most globally up to date demographic and statistical modeling for counting incompleteness
[14, 15] and cause distribution of mortality and uncertainty [13, 17, 19, 20]. The values
obtained in this study are surprisingly much lower than those reported by available interna-
tional records of Iran in GBD and related published articles [3, 6]. After assessing the GBD
reports we did not find any specific data point of cirrhosis from Iran; probably, to predict cir-
rhosis mortality rate of Iran, GBD used the data from neighboring countries which had very
high rates of cirrhosis mortality like Afghanistan, Armenia and Pakistan, using statistical pre-
diction modeling [6, 23]. To the best of our knowledge, there is no published article on cirrho-
sis mortality rate in Iran which collected its data via population-based cohorts, but our results
are consistent with the reports of liver cirrhosis registry on this issue [24]. Besides, hospitaliza-
tion data on cirrhosis in Iran, which is under publication, have consistent results and proves
our estimates.
The age adjusted mortality rate of cirrhosis are decreasing in countries located in East Asia
(eg. China, North Korea and Taiwan), North Africa and Middle East (eg. Saudi Arabia, Iran,
Iraq, Lebanon, Morocco, Egypt), and South Asia (eg. Bangladesh, India, Pakistan). This is in
Fig 4. Age adjusted mortality rate in females and males by age in Iran between 1990 and 2015.
https://doi.org/10.1371/journal.pone.0198449.g004
Liver cirrhosis mortality
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line with the global trend and our findings. Conversely, in Central Asia (eg. Armenia, Azerbai-
jan, Tajikistan, and Turkmenistan) and Eastern European countries (eg. Belarus, Estonia, Rus-
sia, and Ukraine) this trend is increasing [3, 6, 7]. Afghanistan is a neighbor country with the
highest standardized cirrhosis mortality rate in the region; it was 52.53 (34.9–68.61) in 2015.
Among gastrointestinal disease, cirrhosis of liver and hepatic failure are the third main
causes of mortality in Iran. Likewise, the most prevalent gastrointestinal disease diagnosed in a
reference hospital in Tehran was cirrhosis of liver and hepatic failure. [25, 26]. The fact that
liver cirrhosis mortality increased in older age groups is predictable and probably reflects the
natural history of cirrhosis and aging process. An individual exposed to some factor related to
the disease (viral hepatitis, alcohol, metabolic syndrome and other diseases) takes about 20
years to develop cirrhosis. In addition, aging increases the possibility of the fibrotic response
formation[27]. So, the older groups in 2015 represent people that have been exposed to these
exposures in the past and that were probably not submitted to interventions such as vaccina-
tion. In fact, this is one of the great difficulties in studying cirrhosis, based on Iranian data.
According to this study findings, the hepatitis B infection is a major cause of cirrhosis at
national and subnational levels. Hence, hepatitis B control strategies must be the top concern
of health policy makers. The hepatitis B vaccination program, which is a preventive health
strategy, was established in 1993 as a routine child vaccination program[28]. The effectiveness
of this program is obvious due to dropping rate of hepatitis B prevalence in Iran to 3% (95%
Fig 5. Age-adjusted liver cirrhosis mortality (per 100,000) for both sexes in 1990, 2000, 2010, and 2015 in Iran.
https://doi.org/10.1371/journal.pone.0198449.g005
Liver cirrhosis mortality
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CI: 2% to 3%) in 2014[23] to 2.2% (95% CI: 1.9% - 2.6%) in 2016[29]. According to our results,
the cirrhosis death number had increasing pattern until 2000 and then decreased to minimum
level till 2015. This pattern is compatible with maximum coverage of vaccination of hepatitis B
Fig 6. Cause specific liver cirrhosis mortality, age adjusted rate by province in Iran between 1990 and 2010.
https://doi.org/10.1371/journal.pone.0198449.g006
Fig 7. Male to Female age-adjusted liver cirrhosis mortality ratio between 1990 and 2015 by cause in Iran.
https://doi.org/10.1371/journal.pone.0198449.g007
Liver cirrhosis mortality
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in Iran with a lag of time (Fig 2). It seems that the vaccination program has been effective in
reducing cirrhosis mortality. In China the reduction of liver cirrhosis mortality was due to
hepatitis B which is in line with Iran’s pattern of mortality [6, 30]. Possible underlying risk fac-
tors contributing in chronic hepatitis incidence in Iran are reported as: unsafe surgical and
dental procedures, unsafe sexual activity, intravenous (IV) drug use, blood transfusion, male
gender, some particular occupations, and using shared contaminated syringes in prisons[31,
32].Hence, promoted strategies must be considered in designing future prevention policies;
for example training workshops on preventing high risk behaviors. Currently, the availability
of new short term treatments for hepatitis C has resulted in complete cure of many patients
with chronic HCV infection [33]. Cost effective evaluation of providing these treatments for
reducing cirrhosis mortality due to hepatitis C in high risk provincial level in Iran is essential.
The growing epidemic of obesity in Iran may have an increasing role in liver cirrhosis due to
“other causes” in the past two decades. Studies have suggested the increasingly significant
impact of nonalcoholic cirrhosis on cirrhosis mortality [34, 35]. However it is difficult to be
quantified based on our data and future studies are needed on this issue. It is important to
reevaluate nutritional programs of community based on available studies by health policy
makers to reduce the impact of diet on cirrhosis[36]. At this time noninvasive methods are
available for early detection of cirrhosis [37, 38]. It is important for health authorities to utilize
essential screening tools for high risk groups.
Liver cirrhosis due to alcohol consumption is an underling issue in Europe and Latin
America, but in Pacific and Middle East most of the cirrhosis mortality is attributed to hepati-
tis B and hepatitis C infection [1, 39–41]. For example, Egypt has the highest prevalence of
hepatitis C in general population and other population groups. So, the standardized mortality
rate of cirrhosis is correspondingly the highest globally by 103.09(83.32–111.83) in 2015 [31,
42]. Because of religious inhibitions, alcohol consumption is not permitted in Iran, therefore
alcohol use is not considered as a major cause of cirrhosis mortality.
Assessing the incompleteness, misclassification, cause distribution, and finding garbage
and null codes of mortality data are the most important limitations of many mortality studies
[43, 44]. As the strength of this study, we addressed this issue by utilizing internationally
demographic and statistical modeling’s which were mentioned above. As another limitation of
this study, cirrhosis and hepatocellular carcinoma have same major causes such as alcohol con-
sumption, hepatitis B and C; consequently the mortality rate may be underestimated. Also,
increase in deaths in those under 20 years age group could be an artifact of small numbers
However we have used the statistical methods to removes overlaps as much as possible. The
findings of this study are also consistent with hospitalization reports on cirrhosis at national
and provincial levels which were mentioned above. As another strength of this study, we calcu-
lated uncertainty of mortality rates at national and provincial levels using appropriate statisti-
cal methods.
Conclusion
To the best of our knowledge, this study is the first report of cirrhosis mortality trend at the
national and provincial levels during a period of 26 years in Iran. It showed that it is required
to control and screen cirrhosis and common risk factors in high risk age groups. This report is
useful for authors, grant claimants, funding organizations, and policy makers. It could be also
used for future research on burden of this disease which is important for medical education
and policy making. The health care system needs national and subnational estimates of disease
mortality to establish health development programs. Cirrhosis mortality could be diminished
by using new non-invasive methods of cirrhosis screening, hepatitis B vaccination, curable
Liver cirrhosis mortality
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treatment of hepatitis C, and reducing obesity via designing nutritional policies and programs
at national and subnational levels particularly in high risk groups.
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